Cellavita Pesquisas Científicas Ltda.

What Cellavita Pesquisas Científicas Ltda. does

Cellavita Pesquisas Científicas Ltda. is a clinical-stage biotechnology company headquartered in Valinhos, São Paulo, Brazil, with operations referenced in both Brazil and the United States. The company develops allogeneic (heterologous) cell therapy products built around a single proprietary platform, NestaCell®, based on mesenchymal stem cells. Its manufacturing operates under an ISO 5 environment and is positioned for compliance with FDA, EMA, and ANVISA frameworks, including RDC 441/2011, RDC 11/2009, RDC 55/2015, and RDC 508/2021, as well as the Brazilian Pharmacopoeia. The company is led by founder Prof. Dr. Irina Kerkis, whose scientific record includes over 110 published articles, 20 book chapters, and 5 patents, and is supported by an International Scientific Committee and a long-running research collaboration with Instituto Butantan dating to 2004.

The company's clinical activity is anchored by a Phase II trial of NestaCell® in COVID-19, registered on ClinicalTrials.gov with CONEP approval and approximately 90 participants, conducted across multiple Brazilian sites including Casa de Saúde de Campinas, Unifesp, Incor (HC-USP), and SPDM São Paulo. Beyond COVID-19, pre-clinical work is cited across muscular dystrophy, spinal cord injury, multiple sclerosis, and Huntington's disease, indicating a pipeline expansion strategy leveraging the same NestaCell® platform across rare and neurological indications. Intellectual property has been secured through granted patents in the United States and Europe and a registered trademark for NestaCell®.

Cellavita is pre-revenue and pre-commercial, with no traditional marketing or disclosed paying customers; revenue mechanics are not yet defined. Capital structure signals include FINEP (Brazilian Government Innovation Agency) funding approval, providing non-dilutive public funding, while collaboration partners such as Instituto Butantan and the Albert Einstein Pre-Clinical Testing Lab serve as scientific and pre-clinical infrastructure rather than commercial channels. The combination of an ISO 5 manufacturing footprint, multi-jurisdictional IP, and a Phase II clinical program positions the company as an early-stage but internationally-oriented cell therapy asset targeting high-unmet-need indications.

Name

Cellavita Pesquisas Científicas Ltda.

Legal name

Cellavita Pesquisas Científicas Ltda.

Website

https://cellavita.com.br

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

51–100 employees

Short description

Cellavita Pesquisas Científicas Ltda. is a Brazilian clinical-stage biotechnology company developing allogeneic mesenchymal stem cell therapies through its proprietary NestaCell® platform for rare diseases and unmet medical needs.

Ownership category

akta.pro rank

Product category

Cell Therapy / Biotechnology

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

akta.pro secondary industry

Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)

Keywords

• Cell therapy products
• Mesenchymal stem cells
• Clinical-stage biotechnology
• Advanced therapy medicinal products
• Rare disease therapeutics

Headquarters

HQ city

Valinhos, São Paulo

HQ country

Brazil

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Advanced Cell Therapy Products (Pre-commercial): Cellavita is a clinical-stage company developing disruptive and innovative Advanced Cell Therapy products for life-threatening rare diseases and significant unmet medical needs. Revenue model will depend on successful clinical development and regulatory approvals for commercializing cell therapy products.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Cellavita develops disruptive and innovative Advanced Cell Therapy products for the treatment of life-threatening rare diseases and significant unmet medical needs using its proprietary NestaCell® platform based on heterologous mesenchymal stem cells. The company operates as a clinical-stage biotechnology firm conducting Phase II clinical trials, including a COVID-19 study in hospitalized patients on mechanical ventilation, with products manufactured in ISO5 controlled environments meeting FDA, EMA, and ANVISA standards.

Product overview

Cellavita is a clinical-stage biotechnology company that operates a single unified product platform called NestaCell®, a registered trademark advanced cell therapy product with patents granted in the USA and Europe. The company develops heterologous (allogeneic) mesenchymal stem cell products for treating rare debilitating diseases and significant unmet medical needs. The NestaCell® product is manufactured in ISO5 controlled environments and the company conducts clinical trials including a Phase II COVID-19 study using this product platform.

Differentiator

Problem solved

Functional benefit

Brands

• NestaCell®: Proprietary technological platform for advanced cell therapy products - registered trademark with patents granted in USA and Europe

Products and services

• NestaCell® Registered trademark advanced cell therapy product platform using heterologous mesenchymal stem cells for the treatment of life-threatening rare diseases and unmet medical needs. Patented in the USA and Europe. Currently being evaluated in a Phase II clinical trial for COVID-19 in hospitalized patients on invasive mechanical ventilation.

Quantifiable outcome

• >90% of patients showed partial recovery after third transplant in canine encephalomyelitis model (demyelination similar to MS)
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• Instituto ButantancoreStrategic or Co-development Partner · 1 January 2004Research originated at Instituto Butantan in 2004 under Prof. Dr. Irina Kerkis. Prof. Kerkis has been director of the Genetics Laboratory at Instituto Butantan since 2004, with ongoing research collaboration for stem cell studies.
• Albert Einstein Pre-Clinical Testing LaboratorycoreStrategic or Co-development PartnerBiodistribution study conducted in partnership with the Albert Einstein Pre-Clinical Testing Laboratory, validating the safety and distribution profile of CTIPD cells in Huntington's disease models.
• International Scientific CommitteecoreOthersCellavita has assembled a Scientific Committee with experts from around the world to guide clinical investigation paths, supporting the company's intention to conduct multicentric and international studies.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• BrainStorm Cell Therapeutics: BrainStorm's NurOwn is an autologous MSC-based cell therapy with Phase III data in ALS and exploratory programs in MS and other neurodegenerative diseases. Comparable to Cellavita on use of mesenchymal-lineage cells for rare CNS and neuromuscular indications.
• Athersys / Healios: Athersys and partner Healios develop MultiStem, an allogeneic multipotent cell therapy, including for ARDS and COVID-19-related respiratory indications. The therapeutic modality (off-the-shelf cell therapy for critical care indications) directly overlaps with Cellavita's NestaCell® COVID-19/ARDS focus.
• Mesoblast: Mesoblast develops allogeneic mesenchymal stem cell therapies (e.g., remestemcel-L) for inflammatory and immune-mediated diseases, including acute respiratory distress and graft-versus-host disease. It is the closest comparable to Cellavita's NestaCell® allogeneic MSC platform targeting rare and severe indications.
• Pluristem Therapeutics: Pluristem develops placenta-derived allogeneic cell therapy products (PLX cells) for inflammatory, muscle, and pulmonary indications. Its off-the-shelf cell platform and indication overlap (muscle injury, pulmonary disease) make it directly comparable to Cellavita.
• Cynata Therapeutics: Cynata develops Cymerus, an iPSC-derived MSC platform for allogeneic cell therapy in indications such as osteoarthritis, GvHD, and critical care. Comparable to Cellavita as a platform MSC company pursuing multiple rare and inflammatory indications with off-the-shelf manufacturing.

Emerging players

• Capricor Therapeutics: Capricor develops cell-derived exosome and cell therapy candidates (e.g., CAP-1002) for Duchenne muscular dystrophy and other rare diseases. Comparable on rare neuromuscular indications overlapping with Cellavita's pre-clinical MSC programs in DMD and related conditions.
• International Stem Cell Corporation: ISCO develops stem cell-based therapies, including stem cell-derived neural and liver cell products for Parkinson's disease and other neurological conditions. Comparable emerging cell therapy developer with CNS and rare disease focus overlapping with Cellavita's HDPC and neurodegenerative programs.
• Cellect Biotechnology: Cellect develops cell-selection and apoptosis-based cell therapy enabling technologies for use in regenerative medicine. Comparable as a small-cap cell therapy company working on platform technologies relevant to MSC-based product development.

Regional players

• Stempeutics Research: Stempeutics (India) developed Stempeucel, an allogeneic pooled bone marrow MSC product approved in India for Buerger's disease, with additional programs in osteoarthritis and liver disease. Comparable regional MSC developer with similar indication breadth and allogeneic manufacturing model.

Broad incumbents

• TiGenix (now part of Takeda): TiGenix developed Cx601 (darvadstrocel), an allogeneic adipose-derived MSC therapy approved in Europe for complex perianal fistulas in Crohn's disease, now owned by Takeda. Represents an incumbent MSC franchise showing the regulatory and commercial path for allogeneic MSC therapies comparable to NestaCell®.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cellavita

Compliance11 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellavita Pesquisas Científicas Ltda.